Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disea...

por Bruera, Gemma, Ricevuto, Enrico
Publicado no Front Oncol (2020)

Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments

por Bruera, Gemma, Ricevuto, Enrico
Publicado no Pharmgenomics Pers Med (2020)

Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy

por Bruera, Gemma, Russo, Antonio, Galvano, Antonio, Rizzo, Sergio, Ricevuto, Enrico
Publicado no Oncotarget (2016)

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients

por Bruera, Gemma, Cannita, Katia, Giordano, Aldo Victor, Vicentini, Roberto, Ficorella, Corrado, Ricevuto, Enrico
Publicado em 2013

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment...

por BRUERA, GEMMA, CANNITA, KATIA, GIORDANO, ALDO VICTOR, VICENTINI, ROBERTO, FICORELLA, CORRADO, RICEVUTO, ENRICO
Publicado em 2013

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen

por BRUERA, GEMMA, CANNITA, KATIA, GIORDANO, ALDO VICTOR, VICENTINI, ROBERTO, FICORELLA, CORRADO, RICEVUTO, ENRICO
Publicado em 2014

Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemothe...

por Bruera, Gemma, D'Andrilli, Antonio, Simmaco, Maurizio, Guadagni, Stefano, Rendina, Erino Angelo, Ricevuto, Enrico
Publicado no Front Oncol (2020)

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer

por Bruera, Gemma, Massacese, Silvia, Galvano, Antonio, Mas, Antonella Dal, Guadagni, Stefano, Calvisi, Giuseppe, Ciacco, Eugenio, Russo, Antonio, Ricevuto, Enrico
Publicado no Oncotarget (2018)

KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-...

por Bruera, Gemma, Pepe, Francesco, Malapelle, Umberto, Pisapia, Pasquale, Mas, Antonella Dal, Di Giacomo, Daniela, Calvisi, Giuseppe, Troncone, Giancarlo, Ricevuto, Enrico
Publicado no Oncotarget (2018)

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction...

por Bruera, Gemma, Massacese, Silvia, Pepe, Francesco, Malapelle, Umberto, Dal Mas, Antonella, Ciacco, Eugenio, Calvisi, Giuseppe, Troncone, Giancarlo, Simmaco, Maurizio, Ricevuto, Enrico
Publicado no Ther Adv Med Oncol (2019)

Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line...

por Bruera, Gemma, Giuliani, Antonio, Romano, Lucia, Chiominto, Alessandro, Di Sibio, Alessandra, Mastropietro, Stefania, Cosenza, Pierluigi, Ricevuto, Enrico, Schietroma, Mario, Carlei, Francesco
Publicado no BMC Cancer (2019)

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

por Bruera, Gemma, Cannita, Katia, Di Giacomo, Daniela, Lamy, Aude, Frébourg, Thierry, Sabourin, Jean Christophe, Tosi, Mario, Alesse, Edoardo, Ficorella, Corrado, Ricevuto, Enrico
Publicado em 2013

Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice

por Bruera, Gemma, Cannita, Katia, Giordano, Aldo Victor, Manetta, Rosa, Vicentini, Roberto, Carducci, Sergio, Saltarelli, Patrizia, Iapadre, Nerio, Coletti, Gino, Ficorella, Corrado, Ricevuto, Enrico
Publicado em 2014

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II st...

por Bruera, Gemma, Santomaggio, Alessandra, Cannita, Katia, Baldi, Paola Lanfiuti, Tudini, Marianna, De Galitiis, Federica, Mancini, Maria, Marchetti, Paolo, Antonucci, Adelmo, Ficorella, Corrado, Ricevuto, Enrico
Publicado em 2010

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study

por Bruera, Gemma, Massacese, Silvia, Candria, Stefania, Galvano, Antonio, Manetta, Rosa, Giordano, Aldo Victor, Carducci, Sergio, Di Sibio, Alessandra, Ciacco, Eugenio, Russo, Antonio, Ricevuto, Enrico
Publicado no Oncotarget (2018)

Dose-Dense Nonpegylated Liposomal Doxorubicin and Docetaxel Combination in Breast Cancer: Dose-Finding Study

por Ricevuto, Enrico, Cocciolone, Valentina, Mancini, Maria, Cannita, Katia, Romano, Silvio, Bruera, Gemma, Pelliccione, Michela, Adinolfi, Maria Ilaria, Ciccozzi, Antonietta, Bafile, Alberto, Penco, Maria, Ficorella, Corrado
Publicado no Oncologist (2015)

Plasma Proteomic Profiling in Hereditary Breast Cancer Reveals a BRCA1-Specific Signature: Diagnostic and Functional Implications

por Scumaci, Domenica, Tammè, Laura, Fiumara, Claudia Vincenza, Pappaianni, Giusi, Concolino, Antonio, Leone, Emanuela, Faniello, Maria Concetta, Quaresima, Barbara, Ricevuto, Enrico, Costanzo, Francesco Saverio, Cuda, Giovanni
Publicado no PLoS One (2015)

New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting

por Cannita, Katia, Paradisi, Stefania, Cocciolone, Valentina, Bafile, Alberto, Rinaldi, Lucia, Irelli, Azzurra, Lanfiuti Baldi, Paola, Zugaro, Luigi, Manetta, Rosa, Alesse, Edoardo, Ricevuto, Enrico, Ficorella, Corrado
Publicado no Cancer Med (2016)

Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy...

por Guadagni, Stefano, Fiorentini, Giammaria, Mambrini, Andrea, Masedu, Francesco, Valenti, Marco, Mackay, Andrew Reay, Sarti, Donatella, Ricevuto, Enrico, Clementi, Marco, Catarci, Marco, Lazzarin, Gianni, Bruera, Gemma
Publicado no Oncotarget (2019)

Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer

por Bruera, Gemma, Di Staso, Mario, Bonfili, Pierluigi, Galvano, Antonio, Manetta, Rosa, Coletti, Gino, Vicentini, Roberto, Guadagni, Stefano, Ficorella, Corrado, Di Cesare, Ernesto, Russo, Antonio, Ricevuto, Enrico
Publicado no Oncotarget (2018)